Expanding Access. Accelerating Growth. Empowering Global Health.

MSN has built a strong presence across LATAM with operations in 15 countries, led from its regional headquarters in Bogotá, Colombia. With expertise in navigating diverse healthcare and regulatory systems, MSN is focused on bridging therapy gaps by expanding access to advanced specialty and oncology treatments. Supported by a portfolio of 100+ molecules and 200+ SKUs, the region is driven by strong local partnerships, patient-centric initiatives, and a team of 400+ professionals. Key brands in the region include Ipoprin, Dismigras, Macitent, Epnone, and Silotrif.

Cardiovascular | Oncology | Antidiabetic | Pain Management | CNS, Respiratory | Urology | Anti-infectives | Nutraceuticals

Middle East

MSN is steadily expanding its presence across the MENA region with operations spanning 14 countries, led from its regional headquarters in Dubai, UAE. Through strategic collaborations and the establishment of Novadoz Hobail International LLC (NHI) in partnership with Al Hobail, MSN is strengthening local healthcare ecosystems, reducing import dependency, and advancing technology transfer in Saudi Arabia. Focused on bridging critical therapy gaps, the region delivers high-quality and affordable care through a portfolio of 50+ molecules and 80+ SKUs across major therapy areas. Supported by strong regional partnerships and a dynamic team, MSN continues to improve healthcare accessibility, disease awareness, and patient outcomes. Key brands in the region include Neprivas, MSN Dasatinib, MSN Dapagliflozin, MSN Deferasirox, and Tepakin.

Cardiovascular | Oncology | Antidiabetic | Pain Management | CNS | Respiratory | Urology |Anti-infectives | Gastroenterology

Africa

MSN has established a strong presence across Africa with operations in 27 countries, supported by regional offices in Nairobi (Kenya), Addis Ababa (Ethiopia), and Johannesburg (South Africa). Focused on improving access to affordable and quality healthcare, MSN is actively bridging therapy gaps through portfolio diversification and expansion into specialty care and oncology. Backed by a portfolio of 90+ molecules and 200+ SKUs across major therapy areas, the region is driven by strong disease awareness initiatives, HCP education, patient support programs, and a skilled team of 450+ professionals with deep regulatory and market expertise. Key brands in the region include Pregasafe, Ldnil, Epnone, Safetelmi H, and Dismigras.

Cardiovascular | Pain Management | Oncology | Antidiabetic | CNS | Respiratory | Urology | Anti-infectives | Gastroenterology | Nutraceuticals

MSN is steadily expanding across fast-growing ASEAN healthcare markets with operations in 9 countries, supported by regional offices in Hyderabad (India) and Jakarta (Indonesia). Strengthened by a greenfield manufacturing facility in Lippo Karawaci, Indonesia, MSN is enhancing localized access to high-quality and affordable therapies across the region. With a strong focus on regulatory compliance, supply reliability, and commercial excellence, the region is backed by a portfolio of 50+ molecules and 80+ SKUs across major therapy areas. Through disease awareness initiatives, HCP education, and patient support programs, MSN continues to improve healthcare access and outcomes, supported by an agile team of 200+ professionals. Key brands in the region include Rancv, Epnone, Ldnil, Febuday, and Metsafe ER.

Cardiovascular | Pain Management | Oncology | Antidiabetic | CNS | Respiratory | Urology | Anti-infectives | Gastroenterology

MSN has established a strong presence across the CIS region with operations in 5 countries, led from its regional headquarters in Almaty, Kazakhstan. Committed to improving access to high-quality and affordable medicines, MSN is strategically expanding its portfolio to bridge therapy gaps and strengthen its presence in specialty care and oncology. Supported by a growing portfolio of 20+ molecules and 30+ SKUs across key therapy areas, the region focuses on advancing disease awareness, HCP education, and patient support initiatives to improve diagnosis, access, and clinical outcomes. Backed by a dedicated team of 70+ professionals, MSN continues to drive market expansion and stakeholder engagement across the region. Key brands include MSN Azacitidine, MSN Thiotepa, Prasusafe, MSN Eltrombopag, and Birato.

Cardiovascular | Oncology | Pain Management | Anti-infectives | Urology

MSN has built a robust presence across the CEE region with operations in 13 countries, led from its regional headquarters in Warsaw, Poland. Driven by a strong commitment to quality, compliance, and sustainable growth, MSN delivers a diverse portfolio of 50+ molecules and 80+ SKUs aligned with evolving healthcare needs and international quality standards. The region is focused on improving clinical outcomes through strong stakeholder engagement, reliable supply networks, and strategic partnerships across institutional and private healthcare channels. Supported by a dedicated team of 90+ professionals, MSN continues to strengthen its regional footprint and market reach. Key brands in the region include MSN Oseltamivir, MSN Azacitidine, MSN Atorvastatin, MSN Dabigatran, and MSN Abiraterone.

Cardiovascular | Anti-infectives | Pain Management | Oncology | Antidiabetic | CNS | Respiratory | Urology | Nutraceuticals